中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 7
Jul.  2022
Turn off MathJax
Article Contents

Clinical cure of the non-dominant population in chronic hepatitis B patients with HBsAg>3000 IU/mL: A report of two cases

DOI: 10.3969/j.issn.1001-5256.2022.07.027
Research funding:

National Science and Technology Major Project during the 13th Five-Year Plan Period (2017ZX10203201-002-002)

More Information
  • Corresponding author: GAN Jianhe, ganjianhe@suda.edu.cn(ORCID: 0000-0002-1288-0178)
  • Received Date: 2021-08-10
  • Accepted Date: 2021-11-01
  • Published Date: 2022-07-20
  • loading
  • [1]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
    [2]
    Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on clinical cure (functional cure) of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.
    [3]
    CHAN H, CHAN F, HUI AJ, et al. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study[J]. J Viral Hepat, 2019, 26(1): 126-135. DOI: 10.1111/jvh.13000.
    [4]
    HU P, SHANG J, ZHANG WH, et al. HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study[J]. Chin J hepatol, 2018, 26(10): 756-764. DOI: 10.3760/cma.j.issn.1007-3418.2018.10.005.

    胡鹏, 尚佳, 张文宏, 等. 核苷(酸)类似物治疗部分应答的乙型肝炎患者通过聚乙二醇干扰素α-2a治疗获得HBsAg消失: New Switch研究[J]. 中华肝脏病杂志, 2018, 26(10): 756-764. DOI: 10.3760/cma.j.issn.1007-3418.2018.10.005.
    [5]
    HOU JL, WEI L, WANG GQ, et al. Chinical cure of hepatitis B: consensus and controversy[J]. Chin J hepatol, 2020, 28(8): 636-639. DOI: 10.3760/cma.j.cn501113-20200722-00409.

    侯金林, 魏来, 王贵强, 等. 乙型肝炎临床治愈: 共识与争议[J]. 中华肝脏病杂志, 2020, 28(8): 636-639. DOI: 10.3760/cma.j.cn501113-20200722-00409.
    [6]
    HAN MF, WU D, TAN DM, et al. Combination/Sequential Therapy with ETV, Peg-IFN alpha-2b and GMCSF Enhanced HBsAg Loss and Appearance of HBsAb in NA Suppressed CHB Patients (the Anchor A Study): An Interim Analysis[C]. AASLD. Washington, 2017.
    [7]
    WU FP, YANG Y, LI M, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen≤1500 IU/mL: An observational study[J]. World J Gastroenterol, 2020, 26(13): 1525-1539. DOI: 10.3748/wjg.v26.i13.1525.
    [8]
    JIN Y, HUANG CY, WEI FL, et al. Combination therapy in HBeAg-positive chronic hepatitis B patients with poor virological response/HBV resistance to NAs[J]. Infect Dis Info, 2015, 28(5): 273-278. DOI: 10.3969/j.issn.1007-8134.2015.05.005.

    金怡, 黄春洋, 魏飞力, 等. 联合治疗策略在应答不佳/耐药HBeAg阳性慢性乙型肝炎患者中的临床研究[J]. 传染病信息, 2015, 28(5): 273-278. DOI: 10.3969/j.issn.1007-8134.2015.05.005.
    [9]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [10]
    LI M, ZHANG L, LU Y, et al. Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic hepatitis B after treatment with pegylated interferon α-2a[J]. Virol Sin, 2021, 36(2): 311-320. DOI: 10.1007/s12250-020-00290-7.
    [11]
    MA Y, WANG J, XIONG F, et al. Extended duration therapy regimens based on Pegylated interferon for chronic hepatitis B patients focusing on hepatitis B surface antigen loss: A systematic review and meta-analysis[J]. Infect Genet Evol, 2020, 85: 104492. DOI: 10.1016/j.meegid.2020.104492.
    [12]
    BAO X, GUO J, XIONG F, et al. Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs[J]. Int J Infect Dis, 2020, 96: 562-566. DOI: 10.1016/j.ijid.2020.05.041.
    [13]
    LAMPERTICO P, MESSINGER D, CORNBERG M, et al. A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B[J]. Ann Gastroenterol, 2018, 31(6): 712-721. DOI: 10.20524/aog.2018.0300.
    [14]
    CAO W, LI M, ZHANG L, et al. The characteristics of natural killer cells in chronic hepatitis B patients who received PEGylated-interferon versus entecavir therapy[J]. Biomed Res Int, 2021, 2021: 2178143. DOI: 10.1155/2021/2178143.
    [15]
    WANG JY, LI TJ, FU H, et al. Clinical and immunological characteristics of rapid decline of HBsAg at early stage of anti-HBV treatment with peginterferon[J]. Chin J Infect Chemother, 2021, 21(5): 557-565. DOI: 10.16718/j.1009-7708.2021.05.010.

    王嘉悦, 李天驹, 付豪, 等. 聚乙二醇干扰素治疗慢性乙型病毒性肝炎早期HBsAg快速下降的临床及免疫学特征研究[J]. 中国感染与化疗杂志, 2021, 21(5): 557-565. DOI: 10.16718/j.1009-7708.2021.05.010.
    [16]
    MARCELLIN P, AHN SH, MA X, et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B[J]. Gastroenterology, 2016, 150(1): 134-144. e10. DOI: 10.1053/j.gastro.2015.09.043.
    [17]
    HAN M, JIANG J, HOU J, et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α 2a: 1 year follow-up of the OSST study[J]. Antivir Ther, 2016, 21(4): 337-344. DOI: 10.3851/IMP3019.
    [18]
    SUN J, DING H, CHEN G, et al. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China[J]. BMC Gastroenterol, 2019, 19(1): 65. DOI: 10.1186/s12876-019-0981-5.
    [19]
    LEE SK, KWON JH, LEE SW, et al. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B[J]. Liver Int, 2021, 41(2): 288-294. DOI: 10.1111/liv.14701.
    [20]
    REN P, CAO Z, MO R, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk[J]. Expert Opin Biol Ther, 2018, 18(10): 1085-1094. DOI: 10.1080/14712598.2018.1518423.
    [21]
    LI SY, LI H, XIONG YL, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study[J]. J Viral Hepat, 2017, 24(Suppl 1): 12-20. DOI: 10.1111/jvh.12755.
    [22]
    DONG Y, LI M, ZHU S, et al. De novo combination antiviral therapy in e antigen-negative chronic hepatitis B virus-infected paediatric patients with advanced fibrosis[J]. J Viral Hepat, 2020, 27(12): 1338-1343. DOI: 10.1111/jvh.13372.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Article Metrics

    Article views (768) PDF downloads(69) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return